来源: Pharmaceutical Technology
来源: Pharmaceutical Technology
Close Up Of Senior Man Suffering With Parkinson’s disease. Selvita believes its collaboration with the University of Oxford could produce novel new treatments for Parkinson’s Disease. Source: Getty Images / Highwaystarz-Photography 来源: Pharmaceutical Technology
The Polish drug discovery and service provider Selvita has announced a new collaboration with the University of Oxford to advance the development of Parkinson’s disease therapies. PepSetsTM and their Applications
Peptide libraries are a powerful tool in biological research for screening large numbers of peptides in the search for the few, critical bioactive peptides.
Mimotopes PepSets are custom-synthesized peptide libraries supplied unpuried for fast, efcient screening work. These sets of chemically synthesized individual peptides are made
on a small scale using Mimotopes’ unique proprietary parallel array synthesis platform. PepSets comprising hundreds, or even thousands of peptides, are rapidly synthesized and shipped within a few weeks of ordering. 来源: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
-->By downloading this case study, you acknowledge that GlobalData may share your information with Mimotopes Thematic and that your personal data will be used as described in their Privacy Policy Submit
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Please check your email to download the Whitepaper.
Parkinson’s is caused by a build-up of alpha-synuclein, a small protein, forming aggregates inside vulnerable neurons. Cells are then unable to efficiently clear these aggregates, potentially killing neurons and allowing the disease to progress. 来源: Pharmaceutical Technology
ReportsParkinson’s Disease - Global Drug Forecast and Market Analysis to 2029 GlobalData
来源: Pharmaceutical Technology
ReportsParkinson's Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Playe... GlobalData The team at Oxford, led by George Tofaris, PhD, Professor of Neurology and Translational Neuroscience at the university, has identified key protein disposal factors that affect alpha-synuclein aggregation. Selvita believes these could be important drug targets for disease modification, preventing its progression further, as per a 5 June press release. In an email to Pharmaceutical Technology, a Selvita spokesperson stated the company’s plans to build from the team’s research to develop protein degraders. By combining academic knowledge of the disease’s biology from Oxford, and Selvita’s own technical drug discovery capabilities, the company believes the collaboration best positioned them to develop protein degraders. Parkinson’s disease is the second most common neurodegenerative disease, with roughly seven million people affected worldwide. Despite this, existing treatments are only symptomatic, unable to slow or stop the disease’s progression. A GlobalData analysis found a lack of disease-modifying therapies (DMTs) for Parkinson’s was one of the highest unmet needs. Any company that could provide DMTs would have ample opportunities for market entry, as they could bring about a major shift in patient treatment.
Across the seven major markets (US, UK, Japan, Germany, France, Spain and Italy) the market for Parkinson’s disease treatment is set to grow significantly over the next few years, from $4.6bn in 2023 to $11.5bn. The US market is driving this growth, forecasted to nearly triple from $2.4bn in 2023 to $7.4bn by 2029, as per GlobalData.
At this stage, the Selvita spokesperson said it would be premature to commit to any development timeline, but added that they were hopeful to see applications go to trial in the future.
Early R&D projects coverage on Pharmaceutical Technology is supported by Mimotopes.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
PepSetsTM and their Applications
Peptide libraries are a powerful tool in biological research for screening large numbers of peptides in the search for the few, critical bioactive peptides.
Mimotopes PepSets are custom-synthesized peptide libraries supplied unpuried for fast, efcient screening work. These sets of chemically synthesized individual peptides are made
on a small scale using Mimotopes’ unique proprietary parallel array synthesis platform. PepSets comprising hundreds, or even thousands of peptides, are rapidly synthesized and shipped within a few weeks of ordering. 来源: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
-->By downloading this case study, you acknowledge that GlobalData may share your information with Mimotopes Thematic and that your personal data will be used as described in their Privacy Policy Submit
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Please check your email to download the Whitepaper.
Year France Germany Italy Japan Spain United Kingdom United States
2019 121.03 578.55 134.29 644.01 105.83 121.46 1809.79
2020 121.31 573.68 134.18 667.06 105.74 121.97 2047.18
2021 121.65 582.45 135.06 694.66 108.52 121.88 2201.58
2022 123.88 592.76 136.43 727.51 113.65 121.06 2454.66
2023 127.93 603.83 139.29 756.99 119.56 123.35 2695.67
2024 135.23 621.67 144.23 778.77 124.95 130.11 3025.33
2025 154.41 653 152.57 793.72 132.98 138.15 3537.76
2026 184.52 706.16 164.95 846.33 144.8 148.97 4833.98
2027 256.18 947.17 215 885.81 199.27 179.63 5657.51
2028 360.63 1257.17 329.89 935.27 308.88 219.35 6376.5
2029 471.86 1556.14 426.22 1007.13 385.65 257.36 7390.18